Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19914461 | 0.95 | ALDH1A1 (0.38) | ALDH1A1ADH1BADH1CADH1AADH7 | |
| SCHEMBL19914450 | 0.95 | ALDH1A1 (0.38) | ALDH1A1ADH1BADH1CADH1AADH7 | |
| SCHEMBL27114928 | 0.93 | ALDH1A1 (0.36) | ALDH1A1ADH1BADH1CADH1AADH7 | |
| SCHEMBL13066300 | 0.92 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23079165 | 0.92 | ALDH1A1 (0.40) | ALDH1A1ADH1BADH1CADH1AADH7 | |
| SCHEMBL18434949 | 0.89 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1108640 | 0.87 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL15291359 | 0.87 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL22259482 | 0.85 | ALDH1A1 (0.38) | ALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL12992966 | 0.83 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | ALDH1A1 127/4885ADH1B 670/4885ADH1C 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.